
RAS(ON) Inhibitors May Overcome Resistance to Traditional KRAS Inhibitors in Solid Tumors
With the development of novel RAS(ON) inhibitors such as zoldonrasib (RMC-9805) and daraxonrasib (RMC-6236), investigators are aiming to surmount acquired resistance in patients with pretreated solid tumors following treatment with currently available RAS …